Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings Limited announced that its product, Amoxicillin Sodium and Clavulanate Potassium for Injection, has passed the Consistency Evaluation by the China National Medical Products Administration. This approval is expected to strengthen the company’s position in the anti-infective field and enhance its market presence, while continuing to focus on research and development for future growth.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited, incorporated in the Cayman Islands, operates in the pharmaceutical industry. The company focuses on the development and production of generic drugs, with a strong emphasis on anti-infective medications such as broad-spectrum penicillin antibiotics.
Average Trading Volume: 11,943,488
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.64B
See more data about 3933 stock on TipRanks’ Stock Analysis page.